# Medigen Vaccine Biologics > biotech company **Wikidata**: [Q101251708](https://www.wikidata.org/wiki/Q101251708) **Wikipedia**: [English](https://en.wikipedia.org/wiki/Medigen_Vaccine_Biologics_Corporation) **Source**: https://4ort.xyz/entity/medigen-vaccine-biologics ## Summary Medigen Vaccine Biologics is a Taiwanese biotechnology company established on October 12, 2012, headquartered in Hsinchu Science Park. It is known for developing the first domestically produced COVID-19 vaccine in Taiwan and operates as a public company listed on the Taipei Exchange. The company focuses on vaccine and biologics research, production, and innovation. ## Key Facts - Founded on October 12, 2012. - Headquartered in Hsinchu Science Park, Taiwan. - Legal form: Public company (listed on the Taipei Exchange under stock code 6547 since April 17, 2018). - GUI Number: 53943057. - Primary industries: Pharmaceutical and biotechnology. - Developed the first Taiwanese COVID-19 vaccine (Medigen COVID-19 vaccine). - Operates under aliases including MVC, Medigen Vaccine Biologics Corporation, and 高端疫苗生物製劑股份有限公司. - Website available in English and Traditional Chinese: https://www.medigenvac.com/. - Recognized in Wikimedia projects with sitelinks in English, French, Chinese, and Commons. ## FAQs **What is Medigen Vaccine Biologics' main product?** The company is best known for developing the Medigen COVID-19 vaccine, the first domestically produced COVID-19 vaccine in Taiwan. **When and where was Medigen Vaccine Biologics founded?** It was founded on October 12, 2012, in Taiwan, with headquarters in Hsinchu Science Park. **Is Medigen Vaccine Biologics a public company?** Yes, it is listed on the Taipei Exchange under stock code 6547 since April 17, 2018. **What other names is Medigen Vaccine Biologics known by?** It is also referred to as MVC, Medigen Vaccine Biologics Corporation, and 高端疫苗生物製劑股份有限公司, among other aliases in multiple languages. **Does Medigen Vaccine Biologics have an international presence?** While based in Taiwan, the company collaborates with international organizations and has multilingual online presence, including English and Traditional Chinese. ## Why It Matters Medigen Vaccine Biologics plays a critical role in Taiwan’s biotechnology sector and public health infrastructure. As the developer of the first locally produced COVID-19 vaccine, it demonstrated Taiwan’s capacity for rapid medical innovation during the pandemic. The company contributes to global health security through vaccine research and production, while its public listing supports economic growth by enabling broad investment in Taiwanese biotech innovation. ## Notable For - First Taiwanese company to develop a domestically produced COVID-19 vaccine. - Publicly traded on the Taipei Exchange, enhancing transparency and access to capital. - Utilizes virus-like particle (VLP) technology for vaccine development. - Collaborates with international partners, including the World Health Organization (WHO) and foreign governments. ## Body ### History and Founding Medigen Vaccine Biologics was founded on October 12, 2012, in Taiwan. It emerged as a key player in the biotechnology sector, particularly during the COVID-19 pandemic, when it developed the first domestically produced vaccine in Taiwan. The company’s inception marked a strategic effort to bolster local biomedical research and reduce reliance on foreign vaccine supplies. ### Corporate Structure and Ownership Medigen operates as a public company (legal form: public company) listed on the Taipei Exchange since April 17, 2018, under stock code 6547. Its GUI Number is 53943057. As a publicly traded entity, ownership is distributed among shareholders, with governance overseen by a board of directors. This structure distinguishes it from private companies, enabling broader capital raising and public investment. ### Products and Innovation The company specializes in vaccine and biologics development, with a focus on virus-like particle (VLP) technology. Its most notable product is the Medigen COVID-19 vaccine, a critical milestone in Taiwan’s pandemic response. This vaccine underwent phase III clinical trials and was approved for emergency use in Taiwan and other countries, including Paraguay and Bahrain. ### Global Collaboration and Recognition Medigen engages in international partnerships, including collaborations with the World Health Organization (WHO) and foreign governments, to advance vaccine distribution and research. Its work has been recognized globally, with multilingual support on its official website (English and Traditional Chinese) and presence in Wikimedia projects across multiple languages (English, French, Chinese, and Commons). ### Headquarters and Operations The company is headquartered in Hsinchu Science Park, a major hub for Taiwanese tech and biotech industries. This location facilitates access to research infrastructure and talent, supporting its mission to develop innovative biomedical solutions. ### Public Listing and Economic Impact Medigen’s listing on the Taipei Exchange (stock code 6547) since 2018 reflects its integration into Taiwan’s financial markets. This public status enhances its ability to raise capital for research and development, contributing to the growth of Taiwan’s biotechnology sector and attracting international investment. ### Technology and Research Medigen’s use of VLP technology underscores its commitment to advanced biomedical research. VLP platforms allow for the creation of vaccines that mimic viral structures without containing live viruses, offering safety and adaptability for addressing emerging infectious diseases. ### Cultural and Linguistic Identity The company is recognized by multiple aliases, including its Chinese name (高端疫苗生物製劑股份有限公司) and Japanese transliterations (メディジェン・ワクチン・バイオロジクス). This linguistic diversity reflects its engagement with regional and global stakeholders in the biotech industry.